ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 511. Hotta VT, Tendolo SC, Rodrigues AC, Fernandes F, Nastari L, Mady C. Limitations in the diagnosis of noncompaction cardiomyopathy by echocardiography. Arq Bras Cardiol. 2017;109(5):483-8. 512. WanJ,ZhaoS,ChengH,LuM,JiangS,YinG,etal.Varieddistributionsof late gadolinium enhancement found among patients meetingcardiovascular magnetic resonance criteria for isolated left ventricularnon-compaction. J Cardiovasc Magn Reson. 2013 Feb 20;15:20. 513. Deshmukh A, Kumar G, Pant S, Rihal C, Murugiah K, Mehta JL. Prevalence of Takotsubo cardiomyopathy in the United States. AmHeart J. 2012;164(1): 66-71.e1. 514. edfors B, Vedad R, Angerås O, Råmunddal T, Petursson P, Haraldsson I, et al. Mortality in Takotsubosyndrome is similar to mortality in myocardial infarction -A report from the SWEDEHEART registry. Int JCardiol. 2015 Apr 15;185:282-9. 515. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al. Current state of knowledge on Takotsubo syndrome: a position statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18(1):8-27. 516. Pelliccia F, Kaski JC, Crea F, Camici PG. Pathophysiology of Takotsubo syndrome. Circulation. 2017;135(24):2426-41. 517. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): amimic of acutemyocardialinfarction. AmHeart J. 2008;155(3):408-17. 518. Brunetti ND, Santoro F, De Gennaro L, Correale M, Gaglione A, Di Biase M, et al. Combined therapy with beta-blockers and ACE-inhibitors/ angiotensin receptor blockers and recurrence of Takotsubo (stress) cardiomyopathy: a meta-regression study. Int J Cardiol. 2017 Mar 1;230:281-3. 519. De Santis V, Vitale D, Tritapepe L, Greco C, Pietropaoli P. Use of levosimendan forcardiogenic shock in a patient with the apical ballooning syndrome. Ann Intern Med. 2008;149(5):365-7. 520. Kurisu S, Kihara Y. Clinical management of Takotsubocardiomyopathy. Circ J. 2014;78(7):1559-66. 521. Ayub-FerreiraSM,SouzaJD,AlmeidaDR,BiselliB,AvilaMS,Colafranceschi AS, et al. Diretriz de Assistência Circulatória Mecânica da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2016;107(2 Suppl 2):1-33. 522. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail. 2016;4(6):464-72. 523. Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1597-605. 524. Lupón J,Díez-LópezC,deAntonioM,DomingoM,ZamoraE,MolinerP,et al. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail. 2017;19(12):1615-23. 525. Pascual-FigalDA,Ferrero-GregoriA,Gomez-Otero I,VazquezR,Delgado- Jimenez J, Alvarez-Garcia J, et al; MUSIC and REDINSCOR I research groups. Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. Int J Cardiol. 2017 Aug 1;240:265-70. 526. Lam CS, Solomon SD. Fussing over the middle child: heart failure with mid-range ejection fraction. Circulation. 2017;135(14):1279-80. 527. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al; CHART-2 Investigators. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail. 2017;19(10):1258-69. 528. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455-62. 529. Hogg K, McMurray J. The treatment of heart failurewith preserved ejection fraction ("diastolic heart failure"). Heart Fail Rev. 2006;11(2):141-6. 530. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018 Feb 12. [Epub ahead of print]. 531. Koh AS, Tay WT, Teng TH, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1624-34. 532. Tromp J, Voors AA, LamCS. Heart failurewithmid-range ejection fraction: causes and consequences. Eur J Heart Fail. 2018;20(4):660-2. 533. Wilcox JE, Mann DL. Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again? Eur Heart J. 2018;39(1):36-8. 534. Cleland JG, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJ, et al; Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26-35. 535. Nauta JF, Hummel YM, vanMelle JP, van der Meer P, LamCS, Ponikowski P, et al. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? Eur J Heart Fail. 2017;19(12):1569-73. 536. Sepúlveda C, Marlin A, Yoshida T, Ullrich A. Palliative care: the World Health Organization's global perspective. J Pain Symptom Manage. 2002;24(2):91-6. 537. Jaarsma T, Beattie JM, Ryder M, Rutten FH, McDonagh T, Mohacsi P, et al; AdvancedHeart Failure Study Group of theHFA of the ESC. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11(5):433-43. 538. Allen LA, Matlock DD, Shetterly SM, Xu S, Levy WC, Portalupi LB, et al. Use of risk models to predict death in the next year among individual ambulatory patients with heart failure. JAMA Cardiol. 2017;2(4):435-41. 539. Canadian Cardiovascular Society. Managing the symptoms of advancing heart failure. [Cited in 2018 Feb 13]. Available from: http://www.ccs. ca/eguidelines/Content/Topics/HeartFailure/8%20Community%20 Management%20of%20Heart%20Failure.htm. 540. Whellan DJ, Goodlin SJ, Dickinson MG, Heidenreich PA, Jaenicke C, Stough WG, et al; Quality of Care Committee, Heart Failure Society of America. End-of-life care in patients with heart failure. J Card Fail. 2014;20(2):121-34. 541. Brasil. Conselho Federal de Medicina. Resolução 1.805/2006 de 09/11/2006. Fase terminal de enfermidades graves e incuráveis é permitido ao médico limitar ou suspender procedimentos e tratamentos que prolonguem a vida do doente, respeitando assistência integral do paciente. Diário Oficial da União, de 28/11/2006, seção I, pág. 169. 542. Esporcatte R, Rangel FO, Mourilhe-Rocha R. Cardiologia Intensiva: bases práticas: finitude da vida: eutanásia e distanásia. Rio de Janeiro: Ed. Revinter; 2005. p.337-46. 543. Koop CE. Decisions at the end of life: have we come of age? BMC Medicine. 2010;8:57. 544. Bomtempo TV. O direito de morrer com dignidade. [Citado em 2018 fev 15]. Disponível em: http://www.ambito-juridico.com.br/site/index. php?n_link=revista_artigos_leitura&artigo_id=10386. Acesso em 15/02/2018. 545. Ribeiro AL, Duncan BB, Brant LC, Lotufo PA, Mill JG, Barreto SM. Cardiovascular health in Brazil. Circulation. 2016;133:422-433. 546. Stevens B, Verdian L, Pezzulo L, Tomlinson J, Lui V. The economic burden of heart conditions in Brazil. Value in Health. 2016;19:A648. 532